-
Nov 11, 2024 | 
mdpi.com | Matthew Smith |Ali Boolani |Matthew Lee
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
May 24, 2024 | 
urotoday.com | Matthew Smith
Read the Full Video TranscriptAlicia Morgans: Hi. I'm so excited to be here today with Professor Matthew Smith, who is joining me from Massachusetts General Hospital in Boston, as well as joining me recently in Lugano, Switzerland for the APCCC 2024. Thank you so much for being here with me today, Matt. Matthew Smith: Happy to be here. Alicia Morgans: Wonderful.
-
Mar 26, 2024 | 
urologytimes.com | Matthew Smith |Brian Helfand
Two prostate cancer experts discuss treatment decision-making practices for patients with newly diagnosed metastatic disease.
-
Mar 19, 2024 | 
urologytimes.com | Matthew Smith |Brian Helfand
A comprehensive discussion on diagnostic practices in prostate cancer, highlighting imaging practices and the differences between castration-resistant prostate cancer and hormone-sensitive prostate cancer.
-
Dec 29, 2023 | 
milliman.com | Matthew Smith |Noah Champagne |Robert Eaton |Nancy Gu
Should providers steer toward or away from GUIDE? We analyze the requirements and financial implications of CMS’s new model for the support and treatment of Medicare fee-for-service beneficiaries with dementia. Matthew Smith, Noah Champagne, Robert Eaton, Nancy Gu, Greyson Britt
-
Sep 15, 2023 | 
onlinelibrary.wiley.com | Matthew Smith |Jodi Young |Brad Tracy |Jason Soncrant
1 INTRODUCTION Patients with similar diagnoses can have highly variable ‘clinical trajectories’ or prognoses (Tousignant-Laflamme et al., 2022). A prognosis is a prediction of a patient's degree of change or likely status over time (Beattie & Nelson, 2007; Tousignant-Laflamme et al., 2017). Understanding one's prognosis may be useful in avoiding unnecessary care, and reducing medicalisation and overdiagnosis (van der Velden et al., 2020; van Dijk, Faber, Tanke, Jeurissen, & Westert, 2016).
-
Jun 13, 2023 | 
urotoday.com | Matthew Smith
Alicia Morgans interviews Matthew Smith who has made significant contributions to the ARASENS Study. This study focuses on patients with metastatic hormone-sensitive prostate cancer that are eligible for chemotherapy. The ARASENS trial has led to the approval of darolutamide in combination with docetaxel chemotherapy. The ARASENS trial design followed the success of docetaxel in improving survival in patients with metastatic castration-sensitive prostate cancer.
-
Jun 13, 2023 | 
urotoday.com | Matthew Smith
Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here with Dr. Matthew Smith, who is the director of GU Malignancies at Massachusetts General Hospital. Thank you so much for being here with me today. Matthew Smith: Happy to be here. Alicia Morgans: Wonderful. So, Matthew, you have really engaged and participated in the ARASENS Study, which is a study for patients with metastatic hormone sensitive prostate cancer that are eligible for chemotherapy treatment.
-
Jun 6, 2023 | 
bv.world | Matthew Smith
By MATTHEW SMITHA RECENT government survey found that 39 percent of UK businesses had identified a cyberattack on their business in the previous 12 months. In recent days, British Airways, the BBC, Boots, and other major organisations, have had personal data and bank details compromised following the exploitation of a zero-day flaw in file transfer system MOVEit. The BBC has warned employees of stolen data including staff ID numbers, home addresses, national insurance numbers and dates of birth.
-
Mar 1, 2023 | 
urotoday.com | Matthew Smith
Matthew Smith joins Alicia Morgans to discuss the post hoc analysis of the ARASENS study reporting the impact of disease burden and risk on efficacy and safety outcomes. The positive findings from the ARASENS study showed a significant improvement in overall survival, and those results supported the regulatory approval of darolutamide as part of triplet therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC).
